LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

Chien, Kelly S.; Class, Caleb A.; Montalban‐Bravo, Guillermo; Wei, Yue; Sasaki, Koji; Naqvi, Kiran; Gañán-Gómez, Irene; Yang, Hui; Soltysiak, Kelly A.; Kanagal‐Shamanna, Rashmi; Anh, Kim; Kantarjian, Hagop M.

doi:10.1080/10428194.2020.1723014

Cited by 13 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 42 LILRB4 expression has been shown to highly associated with CTLA-4 expression in chronic myelomonocytic leukemia (CMML) samples. 43 In this study, we observed that with the positive correlation between LILRB4 and PD-1, the combination therapy of anti-LILRB4/gp49B and anti-PD-1 mAbs showed higher anti-tumor metastasis ability compared to the monotherapy. These results suggested ICI targeting LILRB4 may provide a novel combination therapeutic approach in several cancer diseases.…”

Section: Discussionmentioning

confidence: 70%

LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs

Kumata

Endo

et al. 2022

OncoImmunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 70%

LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs

Kumata

Endo

et al. 2022

OncoImmunology

View full text Add to dashboard Cite

“…ILT3 expression has been identified in both M4 and M5 AML subtypes (FAB classification) with M4 and M5 patients showing approximately 60% and 100% positivity ( 49 , 50 ). While prevalence of ILT3 positivity is high in both M4 and M5, its expression intensity may change during leukemic disease progression ( 101 , 102 ). Preclinical evaluation of an anti-ILT3 CAR T-cell model has demonstrated efficient effector function in vitro and in vivo against ILT3+ AML cells (MV4-11, PriAML-1, THP-1, PriAML-2, MOLM13, PriMonoctye) with an E:T ratio of 5:1 resulting in between approximately 50% to 90% specific cell lysis compared to only approximately 20% specific cell lysis in non-transduced control T-cells after 4 hours.…”

Section: Targets Under Clinical Investigation For Car T-cell Therapy ...mentioning

confidence: 99%

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia

Schorr

Perna

2022

Front. Immunol.

View full text Add to dashboard Cite

Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the molecular mechanisms underpinning leukemogenesis, standard-of-care therapeutic approaches have not changed over the last couple of decades. Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has shown remarkable clinical outcomes for patients with acute lymphoblastic leukemia (ALL) and is now an FDA-approved therapy. Targeting of myeloid malignancies that are CD19-negative with this promising technology remains challenging largely due to lack of alternate target antigens, complex clonal heterogeneity, and the increased recognition of an immunosuppressive bone marrow. We carefully reviewed a comprehensive list of AML targets currently being used in both proof-of-concept pre-clinical and experimental clinical settings. We analyzed the expression profile of these molecules in leukemic as well normal tissues using reliable protein databases and data reported in the literature and we provide an updated overview of the current clinical trials with CAR T-cells in AML. Our study represents a state-of-art review of the field and serves as a potential guide for selecting known AML-associated targets for adoptive cellular therapies.

show abstract

“…Recently, novel therapeutic regimens were developed with the combination of intensive chemotherapy with a target agent and lower-intensity therapy to prevent progression or relapse [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ]. The assessment of next generation sequencing [ 9 , 10 , 11 , 12 , 13 , 14 ], transcriptomic analysis [ 15 , 16 , 17 , 18 ], ultra-accurate duplex sequencing [ 19 ], optical genome mapping [ 20 ], and measurable residual diseases [ 21 , 22 , 23 ] enhanced the accuracy of prediction for prognosis [ 24 , 25 ]. However, survival still remains poor even with progress in supportive therapy [ 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Advances in Immunotherapies for Hematological Malignancies

Nogami

Sasaki

2022

IJMS

Self Cite

View full text Add to dashboard Cite

Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapies and to reduce the complications associated with their use in combination with other immune checkpoint inhibitors and conventional chemotherapy. Studies of novel therapeutic strategies such as bispecific (tandem or dual) CAR-T, bispecific killer cell engager, trispecific killer cell engager, and dual affinity retargeting therapies are also underway. Because of these studies and the discovery of novel immunotherapeutic target molecules, the use of immunotherapy for diseases initially thought to be less promising to treat with this treatment method, such as acute myeloid leukemia and T-cell hematologic tumors, has become a reality. Thus, in this coming era of new transplantation- and chemotherapy-free treatment strategies, it is imperative for both scientists and clinicians to understand the molecular immunity of hematologic malignancies. In this review, we focus on the remarkable development of immunotherapies that could change the prognosis of hematologic diseases. We also review the molecular mechanisms, development processes, clinical efficacies, and problems of new agents.

show abstract

LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

Cited by 13 publications

References 20 publications

LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs

LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia

Therapeutic Advances in Immunotherapies for Hematological Malignancies

Contact Info

Product

Resources

About